CSL Limited Sponsored ADR (CSLLY)
OTC PINK OTC PINK Primary Summary
CSL signs licensing deal with Eli Lilly for clazakizumab to treat kidney disease
Australia's CSL said on Wednesday it had entered into an exclusive licensing agreement with Eli Lilly and Co , granting it certain rights to develop and commercialise clazakizumab, an antibody aimed at preventing heart-related illness and death in people with end‑stage kidney disease.
CSLLY vs. EXAS: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either CSL Limited Sponsored ADR (CSLLY) or Exact Sciences (EXAS). But which of these two stocks offers value investors a better bang for their buck right now?
CSL Limited (CSLLY) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for CSL Limited (CSLLY), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
CSL Limited Sponsored ADR (CSLLY) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has CSL Limited Sponsored ADR ever had a stock split?
CSL Limited Sponsored ADR Profile
| Biotechnology Industry | Healthcare Sector | Dr. Paul F. McKenzie Ph.D. CEO | OTC PINK Exchange | 12637N204 CUSIP |
| AU Country | 32,698 Employees | 11 Mar 2025 Last Dividend | 2 Mar 2026 Last Split | - IPO Date |
Overview
CSL Limited is a globally prominent biopharmaceutical and vaccine company with its roots firmly planted in Melbourne, Australia since 1916. The company has carved out a significant presence not only in its home country but also across vital markets in the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and beyond. CSL Limited operates with a strategic focus on research, development, manufacturing, marketing, and distribution of innovative biopharmaceutical and vaccine solutions. It is organized into three main segments: CSL Behring, CSL Seqirus, and CSL Vifor, each targeting specific healthcare needs worldwide. Additionally, CSL Limited actively engages in licensing its intellectual property, underscoring its contributions to advancing global healthcare technologies and treatments.
Products and Services
- CSL Behring
This segment caters to a variety of healthcare needs through its diverse portfolio of products. CSL Behring is renowned for its plasma products, contributing to therapies for immunodeficiencies and rare diseases. It also pioneers in gene therapies, offering cutting-edge treatments for genetic disorders. Furthermore, CSL Behring provides recombinant products, marking significant advances in biotechnology for therapeutic uses.
- CSL Seqirus
Specializing in influenza-related products, CSL Seqirus stands out for its proactive approach towards flu prevention and pandemic preparedness. It offers a breadth of seasonal flu vaccines, ensuring public health safety across the globe. Additionally, CSL Seqirus collaborates with governments worldwide, offering pandemic services and solutions aimed at combating influenza outbreaks efficiently and effectively.
- CSL Vifor
With a keen focus on iron deficiency and nephrology, the CSL Vifor segment advances medical treatments in these crucial therapeutic areas. By developing and distributing specialized products, CSL Vifor addresses a range of conditions related to kidney health and iron metabolism, providing essential solutions for patients suffering from these ailments.
